Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines

Acta Haematol (2014) 132 (1): 75–86.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

Marie Brachet-Botineau
Marion Polomski
Heidi Neubauer
Ludovic Juen
Damien Hédou
Marie-Claude Viaud-Massuard
Gildas Prié
Fabrice Gouilleux

Cancers (2020) 12 (1): 240.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

William Vainchenker
Emilie Leroy
Laure Gilles
Caroline Marty
Isabelle Plo
Stefan N. Constantinescu

F1000Research (2018) 7: 82.

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition

E Leroy
S N Constantinescu

Leukemia (2017) 31 (5): 1023.

The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine

Ji Hyun Cheon
Kyeong Seok Kim
Dharmendra Kumar Yadav
Mihyun Kim
Hyung Sik Kim
Sungpil Yoon

Biochemical and Biophysical Research Communications (2017) 490 (4): 1176.

RETRACTED ARTICLE: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia

Zhu Xishan
Lin Ziying
Du Jing
Liu Gang

Scientific Reports (2015) 5 (1)